D13S25 Deletion Probe

FHPC-036

Chromosomal abnormalities on chromosome 13q occur in 16 - 40% of multiple myeloma cases. Deletions affecting the 13q14 band are also the most frequent genetic abnormalities of B-cell Chronic Lymphocytic Leukaemia (B-CLL). Two non-coding RNA genes, DLEU1 and DLEU2 and the genetic marker D13S319 span the pathogenic critical region 13q14.3. DLEU1 is considered to be the most likely CLL-associated candidate tumour suppressor gene within the 13q14 region. It has been postulated that a gene telomeric to the D13S319 marker encompassing D13S25 and 206XF12 may be important in cases where there are hemizygous deletions and that this gene is a putative tumour suppressor gene. The D13S25 deletion probe covers the marker, the telomeric end of DLEU1 and the centromeric end of DLEU7.

5 Tests, 10 Tests

Red/Green

Human

13q14.3

For Research Use Only. Not for use in diagnostic procedures.

Store at minus 20 centigrade

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.